Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden

Open access
Olsson, Håkan L., Ingvar, Christian, Bladström, Anna·2003·Cancer

Abstract

BACKGROUND: The authors previously reported an increased risk of breast carcinoma with longer duration of hormone replacement therapy (HRT) use. It is unclear if different types of HRT confer different risks. METHODS: In this study, a population‐based cohort of 29,508 women were interviewed during 1990–1992 to determine whether there are any differences in breast carcinoma risk according to different types and duration of HRT use. RESULTS: At the end of the follow‐up period in December 2001, the cohort constituted 298,649 person‐years. Slightly more breast carcinoma cases were seen (n = 556) than expected (n = 508.37; standardized morbidity ratio =1.09, 95% confidence interval [CI] = 1.00–1.19). Approximately 3663 women had ever used HRT. In Cox regression models, time to breast carcinoma in relation to duration and type of HRT use was analyzed, adjusting for age at menarche, age at first full‐term pregnancy, parity, age at menopause, family history of breast carcinoma, and age at interview. In women with a natural menopause, a significantly higher risk was observed for longer duration of combined continuous HRT use compared with never users (hazard ratio [HR] = 4.60, 95% CI = 2.39–8.84). Nonsignificant elevated risks also were observed for longer combined sequential (HR = 2.23, 95% CI = 0.90–5.56), gestagen only (HR = 3.74,9 5% CI = 0.94–14.97), and estriol use (HR = 1.89, 95% CI = 0.81–4.39). No increased risk was seen in women after 5 years of nonuse. When studying women who ever used only one type of HRT, even more elevated HRs for gestagen‐containing preparations were seen. The highest risks were associated with the combined continuous and gestagen‐only therapy in women with ≥ 48 months of use. Use of estradiol without progestins did not increase breast carcinoma risk significantly. The authors estimated the cumulative risk of breast carcinoma in a 50‐year‐old woman with gestagen‐containing therapies for ≥ 48 months, with a follow‐up of 10 years, to be 7% (95% CI = 5.4–11.4%) compared with 2% (95% CI = 1.6%–2.9%) for never‐users of HRT. CONCLUSIONS: Longer use of HRT containing progestins significantly elevates breast carcinoma risk whereas estradiol use does not. Continued use of progestins rendered the highest risks. The yearly risk of breast carcinoma for long‐term users of progestins is of the magnitude of 50% the risk of a BRCA1 mutation carrier. Cancer 2003;97:1387–92. © 2003 American Cancer Society. DOI 10.1002/cncr.11205

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.11205

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 169

Metadata

Authors
Olsson, H. L., Ingvar, C., & Bladström, A.
Venue
Cancer
Publisher
Wiley
Published
2003-03-03
Volume
97
Issue
6
Pages
1387-1392
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2135487374
Cited by
169
References
2
FWCI
14.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. https://app.cochat.ai/papers/10.1002/cncr.11205
The paper
Olsson, H. L., Ingvar, C., & Bladström, A. (2003). Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer. https://doi.org/10.1002/cncr.11205

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.